Desteklenen Projeler
23
-
2025 - Devam Ediyor İnsan ve Hayvan Mezenkimal Kök Hücre Eksozomları ile Bitkisel Eksozomlarının Yara İyileşmesi Üzerine Karşılaştırmalı Etkilerinin Araştırılması
Yükseköğretim Kurumları Destekli Proje , BAP Güdümlü
KAYHAN H. (Yürütücü), Taşpınar Şimşek E., KURT B., ÇELEBİ AYLAN S., GÜNEŞ S., GÖKÇEN S., et al.
-
2025 - Devam Ediyor Akut Myeloid Lösemide Yeni Bir Potansiyel İmmün Kontrol Noktası Siglec15'in Analizi
Yükseköğretim Kurumları Destekli Proje , BAP Araştırma Projesi
GÖKÇEN S. (Yürütücü), YEGİN Z. A., KAYHAN H., ÖZKURT Z. N., YAĞCI A. M., SAVAŞ E. M.
-
2025 - 2031 Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)
-
2024 - 2030 A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination with Lenalidomide Versus Rituximab in Combination with Lenalidomide in Relapsed/Refractory Participants with Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)
Diğer Ülkelerin Sanayi Kuruluşları Tarafından Desteklenmiş Proje
Yağcı A. M. (Yürütücü)
-
2024 - 2030 A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Diğer Ülkelerin Sanayi Kuruluşları Tarafından Desteklenmiş Proje
Yağcı A. M. (Yürütücü)
-
2023 - 2030 A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2024 - 2029 SYMPHONY-1: A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
-
2024 - 2029 A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, versus Standard of Care Therapy in Participants with Relapsed/Refractory Aggressive B-cell non- Hodgkin Lymphoma (OLYMPIA-4)
Diğer Ülkelerdeki Özel Organizasyonlar Tarafından Desteklenmiş Proje
Yağcı A. M. (Yürütücü)
-
2024 - 2029 A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
-
2024 - 2029 BTK İnhibitörü ile önceden tedavi uygulanmış Kronik Lenfositik Lösemi /Küçük Lenfositik Lenfomada Araştırmacının Tercihine Göre İdelalisib ve Rutiksimab ya da Bendamustin ve Rutiksimab'a Kıyasla LOXO-305'in Değerlendirildiği Faz 3,Açık Etiketli,Randomiza Çalışma" başlıklı (BRUINCLL-321) protokol numaralı klinik
-
2023 - 2029 A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab, an anti-CD20 × anti-CD3 bispecific antibody in Previously Untreated Participants with Follicular Lymphoma (FL) (OLYMPIA-2))
-
2023 - 2029 A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab, an anti-CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Folliculr Lymphoma (FL) (OLYMPIA-1)
-
2023 - 2029 A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab, an anti-CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)
-
2023 - 2029 Nükseden mantle hücreli lenfomada bcl-2 inh sonrotoklaksın etkinliği
-
2023 - 2029 A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
-
2023 - 2029 A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)
-
2018 - 2028 A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW)
-
2022 - 2026 MOR208C310A Phase 3, multicenter, open-label, randomized trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R- CHOP versus R-CHOP in high-intermediate and high-risk patients with newly diagnosed Diffuse Large B-Cell Lymphoma
-
2021 - 2026 A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
-
2020 - 2026 A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Comparing the Efficacy and Safety of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Alone Versus in Combination with Acalabrutinib in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma / D8227C00001 / ACE-LY-312
-
2019 - 2026 Nüks KML'li hastalarda Radotinibin etkinliği
-
2019 - 2026 A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator's Choice of Chemo immunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
-
2023 - 2025 Polisitemi Vera Hastalarında Hepsidin Mimetik Rusfertidin (PTG-300) Faz 3 Çalışması"
